SecBot SecBot
6-K ·Filed Aug 12, 2026

BWAY

Brainsway Ltd.
BULLISH
Impact 6/10
Horizonmonths Processed3mo ago SEC0001171843-26-005454
Notable filing: 6-K
Actionable Insight ▲ Bullish

The filing confirms strong operating momentum with record shipments and expanding profitability. Monitor next 20-F for sustained revenue growth above 30% and continued improvement in adjusted EBITDA guided at $13-14M for FY2026. The accelerated adoption of Deep TMS and SWIFT protocol supports a positive medium-term outlook.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$16.47
T+0 close · Aug 12, 2026 · via day close
Latest settled
−32.30%
T+60 · $11.15
Vs SPY
−26.83%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 13 $16.47entry
  2. T+1 · 3mo ago −0.91%α −0.71% · $16.32
  3. T+5 · 3mo ago −9.11%α −7.14% · $14.97
  4. T+20 · 2mo ago −15.42%α −13.67% · $13.93
  5. T+60 · 11d ago −32.30%α −26.83% · $11.15
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Brainsway Ltd. furnished an August 2026 investor deck via Form 6-K, presenting strong H1 2026 financial results: revenue grew +35% year-over-year, net income +34%, adjusted EBITDA +141%, and system shipments rose +42% to 125 units. The filing reiterates the company's strategic positioning as a Deep TMS platform leader with 4 FDA indications, expanding reimbursement, and a capital-light clinic network model. The deck is forward-looking and promotional in nature, reinforcing the growth narrative established in the prior 20-F annual report.

Key Facts

  • Q2 2026 system shipments of 125 units, up +42% year-over-year.
  • Revenue growth of +35%, net income +34%, adjusted EBITDA +141%.
  • Gross margin reported at 75%.
  • Remaining Performance Obligations (RPO) grew +$80 million (+30% year-over-year).
  • Operating income increased +314%, cash balance at $62.4 million.
  • 90%+ customer retention rate and 1.3x book-to-bill ratio.
  • More than 1,950 systems installed across 48 states and 6 continents.
  • Valor Equity Partners (largest investor) backs strategic clinic network expansion.
  • Home therapy enabled via $11M convertible investment in Neurolief with call option.
  • Filed on Form 6-K under cover of the 1934 Act, incorporated by reference into existing F-3 and S-8 registration statements.

Financial Impact

Revenue $52.2M in FY2025; H1 2026 revenue +35% YoY; Adj. EBITDA +141%; net income +34%; cash $62.4M

revenuenet_incomeadjusted_ebitdagross_marginoperating_incomecash_balance

Risk Factors

  • Reliance on single large customer as noted in prior annual filing.
  • Patent litigation with Magnus Medical remains a potential overhang.
  • Forward-looking statements are promotional and not guaranteed; reimbursement changes could slow adoption.
  • International expansion carries execution risk across multiple regulatory jurisdictions.

Market Snapshot

Exchange
OTC
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001171843-26-005454
Document: f6k_081226.htm0001171843-26-005454
Document: 0001171843-26-005454-index-headers.html0001171843-26-005454
Document: 0001171843-26-005454-index.html0001171843-26-005454
Document: 0001171843-26-005454.txt0001171843-26-005454

US Market Status

Market Closed · Opens Wed (11h 35m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 12, 2026